GEN Exclusives

More »

GEN News Highlights

More »
Aug 22, 2007

Operon and DNA2.0 Ink Marketing and Technology Development Partnership

  • Operon Biotechnologies, through a partnership with DNA2.0, has entered the gene synthesis market, a growing application area for oligonucleotides.

    DNA2.0 and Operon Biotechnologies will combine their technologies and product lines. The companies believe that adding Operon's oligonucleotide production platform to DNA2.0's gene-synthesis process will increase the speed of synthesis. Operon will co-market DNA2.0's gene-synthesis services.

    “Construction of synthetic genes requires oligos of only the highest quality,” remarks Jeremy Minshull, president of DNA2.0. “Operon's fully automated oligo-synthesis process meets our exacting quality requirements and their speed and responsiveness makes Operon an outstanding partner for DNA2.0 in the gene-synthesis marketplace.”



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?